Trial · NCT03131648
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 | Tralokinumab 300 mg Q2W | 95 | Participants | ||
| Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 | Placebo Q2W | 14 | Participants | ||
| Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16 | Tralokinumab 300 mg Q2W | 150 | Participants | ||
| Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16 | Placebo Q2W | 25 | Participants | ||
| Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16. | Tralokinumab 300 mg Q2W | 119 | Participants | ||
| Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16. | Placebo Q2W | 20 | Participants | ||
| Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16 | Tralokinumab 300 mg Q2W | -25.2 | Standard Error 0.94 | units on a scale | |
| Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16 | Placebo Q2W | -14.7 | Standard Error 1.80 | units on a scale | |
| Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16 | Tralokinumab 300 mg Q2W | -7.1 | Standard Error 0.31 | units on a scale | |
| Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16 | Placebo Q2W | -5.0 | Standard Error 0.59 | units on a scale | |
| Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16 | Tralokinumab 300 mg Q2W | 20 | Participants | ||
| Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16 | Tralokinumab 300 mg Q4W | 14 | Participants | ||
| Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16 | Placebo Q2W | 9 | Participants | ||
| Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16 | Tralokinumab 300 mg Q2W | 28 | Participants | ||
| Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16 | Tralokinumab 300 mg Q4W | 28 | Participants | ||
| Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16 | Placebo Q2W | 10 | Participants | ||
| Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency | Tralokinumab 300 mg Q2W | AEs | 411 | Participants | |
| Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency | Placebo Q2W | AEs | 133 | Participants | |
| Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency | Tralokinumab 300 mg Q2W | SAEs | 23 | Participants | |
| Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency | Placebo Q2W | SAEs | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03131648/results